Clinicopathologic and genomic features of gliosarcomas (Q48695406)

14 February 2018

title

Clinicopathologic and genomic features of gliosarcomas (English)

1 reference

14 February 2018

3

Yeon-Lim Suh

1 reference

14 February 2018

author name string

Dakeun Lee

1

1 reference

14 February 2018

So Young Kang

2

1 reference

14 February 2018

Ji Yun Jeong

4

1 reference

14 February 2018

Jung-Il Lee

5

1 reference

14 February 2018

Do-Hyun Nam

6

1 reference

14 February 2018

publication date

20 January 2012

1 reference

14 February 2018

Journal of Neuro-Oncology

published in

1 reference

14 February 2018

volume

107

1 reference

14 February 2018

issue

3

1 reference

14 February 2018

page(s)

643-650

1 reference

14 February 2018

The endothelial hyperplasia of the cerebral blood vessels with brain tumors, and its sarcomatous transformation

cites work

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Genetic profile of gliosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Mechanisms of chemoresistance to alkylating agents in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Clinical and pathological study of 24 cases of gliosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Clinicopathologic features of primary and postirradiation cerebral gliosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Gliosarcoma: a clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

Relationship between gene amplification and chromosomal deviations in malignant human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0790-3

A clinico-pathological study of 29 cases of gliosarcoma with special reference to two unique variants

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22270848

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22270848

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-011-0790-3

1 reference

14 February 2018

1 reference

14 February 2018